Menactra®

Ingredient

0.5-milliliter (mL) dose of MenQuadfi® to contain 10 µg each of meningococcal A, C, W, and Y polysaccharides conjugated to approximately 55 µg of tetanus toxoid protein carrier

Content

Indication

r active immunization to prevent invasive meningococcal
disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menactra
is approved for use in individuals 9 months through 55 years of age